EAS Conflict of Interest Disclosure Policy
The European Atherosclerosis Society (EAS) wishes to promote independence, objectivity, scientific rigor and a fair balance of representation, in all its activities.
The EAS have adopted a Conflict of Interest (COI) Disclosure Policy for the purpose of providing guidance and avoiding conflicts of interest within the Society. In order to ensure this, individuals participating in the organization of activities on behalf of the Society are expected to disclose their financial or in-kind relationships both with health industry that develop, manufacture, distribute or sell health care materials or services, or other similar organizations/societies that could represent a potential COI. Such relationships exclude personal or family medical care. Full disclosure is expected even when it is not clear whether a relationship or affiliation constitutes a conflicting interest.
EAS recognizes that these relationships do not necessarily imply bias or decrease the value of participation in professional activities.
Disclosure of these relationships is necessary for others to make an informed decision about the impact of the disclosed relationship. For instance, this may be relevant in the context of educational activities of the EAS.
Those requested to complete the form below include: all EAS Officers and members of the Society’s Committees, members of EAS Consensus Position Paper expert panels, and EAS Course Organizers. The forms will be updated annually.
Equity interests Equity interests (or entitlement to same) of stocks, stock options, royalties, etc., including income from patents or copyrights
Director or employee Service as a director or medical officer or employment/engagement by a commercial organisation/ society, whether or not remuneration is provided for such service
Owner enterprise Sole ownership, partnership, or principal of a commercial enterprise
Ownership of patent(s)
Royalties Receipt of royalties, including for intellectual property, such as a device or a diagnostic tool
Company consultant Consultant to company including positions on medical or scientific advisory boards
BAYER, AMGEN, BOEHRINGER-INGELHEIM, NOVARTIS, SANOFI, NOVO NORDISK
Company speaker honorarium Honoraria for speaking at company sponsored meetings or events
ASTRA-ZENECA, LILLY, BAYER, AMGEN, VIATRIS, BOEHRINGER-INGELHEIM, NOVARTIS, SERVIER, SANOFI, NOVO NORDISK
Trial participation Participation in clinical trials (as a professional). Note that you should not include any clinical trials you have participated in as a non-professional (e.g. as a patient).
ASTRA-ZENECA, BAYER, AMGEN, NOVARTIS, SANOFI, NOVO NORDISK
Fellowship, travel grants Support in the form of fellowships, travel grants, gifts, in-kind donations, etc.
Research grants Research grants, partial or full salary support from commercial organisation/society for self or employees for whom you are managerially responsible (i.e. laboratory technical/research fellow).
Other societies /organisations Leadership roles in the following societies/organisations
Hellenic Atherosclerosis Society (past president 2019-2022, member of the EC 2023-)
Publications Manuscripts have been published in collaboration with non-academic co-author of the following scientific articles
Other Any other type of financial or other relationship to the health industry. Note that you should not include any information that could relate to your political opinion, philosophical belief or your personal health.